The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...

The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...

An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...

FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology ...

Capturing the immunotherapy opportunity in myeloid blood cancers In the fourth quarter of 2025, Mendus presented continued positive long-term survival data of the ADVANCE II trial in acute myeloid leu ...

Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...

Exploring the combination with atezolizumab and radiation therapyStudy led by Yale University MADRID, Spain and CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ...

This required urgent treatment with a blood thinner, but risked causing dangerous bleeding as his blood platelets were seriously low due to AML.

– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and ...

Ziftomenib + Venetoclax/Azacitidine in Newly Diagnosed NPM1 -m AML The ongoing KOMET 007 Phase 1a/b trial (NCT05735184) evaluated 40 patients with newly diagnosed NPM1 -m AML as of the September 24, ...

Patients with AML receiving azacitidine and venetoclax had significantly higher quality of life than those receiving intensive induction chemotherapy. Combining the hypomethylating agent (HMA) ...

Ivo Carre, PhD, shares subgroup data that points to potential benefit in younger patients with high-risk MDS. The VERONA (NCT04401748) trial evaluating venetoclax with azacitidine in high-risk ...